Correction to: Small molecule '4ab' induced autophagy and endoplasmic reticulum stress-mediated death of aggressive cancer cells grown under adherent and floating conditions [0.03%]
题为“小分子‘4ab’诱导黏附和悬浮培养的侵袭性癌细胞自噬和内质网应激介导的死亡”的更正
Sameer Ullah Khan,Kaneez Fatima,Umed Singh et al.
Sameer Ullah Khan et al.
ExposoGraph: An Interactive Platform for Carcinogen Bioactivation and Detoxification Pathway Visualization [0.03%]
ExposoGraph：一个用于致癌剂生物活化和解毒途径可视化的交互式平台
Julhash U Kazi,Kenneth J Pienta
Julhash U Kazi
Despite extensive cataloging of carcinogenic exposures by the International Agency for Research on Cancer (IARC) and pharmacogenomic variation by resources such as PharmVar and CPIC, few platforms unify exposure, metabolic activation and de...
JAK/STAT3 axis in breast cancer: opportunities for intervention with natural phytochemical-based nanotherapeutics [0.03%]
基于天然植物化学物质的纳米药物干预乳腺癌中JAK/STAT3轴的潜力
N S Varsha,Nimbagal Raghavendra Naveen
N S Varsha
Breast cancer holds a horrifying picture of being one of the most common cancers across the world and with it, comes an even more troublesome morbidity and mortality scenario, especially for high-grade malignancy, such as triple-negative br...
Exploration of the mechanism by which Ubiquitin-like protein UBD promotes malignant progression of breast cancer [0.03%]
泛素样蛋白UBD促进乳腺癌恶性进展的机制探索研究
Lei Ma,Bei Xie,Rongzhi Zhang et al.
Lei Ma et al.
Ubiquitin D, a ubiquitin-like protein, functions as a potential tumor promoter in various cancers. However, its biological role and clinical significance in breast cancer remain unclear. In this study, we evaluated UBD expression in maligna...
Rho/PAK signaling: a key driver of anthracycline and taxane resistance in breast cancer [0.03%]
Rho/PAK信号传导：乳腺癌中蒽环类和紫杉烷耐药的关键驱动因素
Nurul Syafawani Fizal,Nik Yasmin Umaira Hasnizan,Chien Fung Chong et al.
Nurul Syafawani Fizal et al.
Resistance to anthracyclines and taxanes remains a major barrier to effective breast cancer treatment, particularly in aggressive subtypes such as triple-negative breast cancer. Although these agents form the backbone of systemic chemothera...
Targeting STAT5A via CRISPR/Cas9 restores TKI sensitivity in resistant chronic myeloid leukemia cells [0.03%]
CRISPR/Cas9靶向STAT5A可恢复TKI耐药慢性髓性白血病细胞的敏感性
Besne Çelik,Yağmur Kiraz,Yaren Şahin et al.
Besne Çelik et al.
Therapeutic resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in the clinical management of chronic myeloid leukemia (CML). The transcription factor STAT5A, a principal downstream effector of BCR::ABL1, has emerged a...
Retraction Note: The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer [0.03%]
撤回 notice: c-Myc-LDHA轴通过正向调节糖酵解促进胰腺癌肿瘤进展
Tian-Lin He,Yi-Jie Zhang,Hui Jiang et al.
Tian-Lin He et al.
Diosmetin overcomes resistance to cisplatin in ovarian cancer by suppressing the MAPK signaling pathway [0.03%]
染料木素通过抑制MAPK信号通路克服卵巢癌细胞对顺铂的耐药性
Juan Nie,Hequn Jiang,Runyu Zhou et al.
Juan Nie et al.
Cisplatin (DDP) is a widely used chemotherapeutic agent for ovarian cancer (OC) therapy. However, the adverse effects and frequent resistance to DDP make its therapeutic efficacy suboptimal. Combination treatment with an agent capable of ov...
Correction to: Lovastatin inhibits adipocyte-associated increased proliferation, EMT and aggressiveness of breast cancer cells [0.03%]
Correction to：洛伐他汀抑制脂肪细胞相关增加的乳腺癌细胞增殖、上皮间质转化及恶性程度
V K Soonu,M Divya Lakshmanan,K N Naresh et al.
V K Soonu et al.
Correction to: Glucagon‑like peptide‑1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells [0.03%]
(GLP-1受体激动剂通过激活AMPK逆转乳腺癌细胞的瓦伯格效应代谢转换纠正说明)
Hagai Ligumsky,Sharon Amir,Tammi Arbel Rubinstein et al.
Hagai Ligumsky et al.